Home » Junshi Biosciences’ Mucosal Melanoma Treatment Nabs FDA Fast-Track Status
Junshi Biosciences’ Mucosal Melanoma Treatment Nabs FDA Fast-Track Status
The FDA has granted Junshi Biosciences a Fast-Track designation for toripalimab as a first-line treatment for mucosal melanoma.
The agency has also cleared the monoclonal antibody for a phase 3 trial in combination with axitinib as a first-line treatment for patients suffering from advanced mucosal melanoma.
Toripalimab received a Breakthrough Therapy designation from the FDA in September for treating metastatic nasopharyngeal carcinoma.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May